THE EFFECT OF STATIN USE ON VASCULAR FUNCTION IN HYPERTENSIVE SUBJECTS

他汀类药物的使用对高血压患者血管功能的影响

• 批准号: 7607464
• 负责人: PAMELA OUYANG
• 金额: $ 0.05万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607464
• 关键词: Atherosclerosis; Blood; Blood Vessels; Cardiovascular system; Cholesterol; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Functional disorder; Funding; Grant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Individual; Inflammation; Institution; Lipids; Metabolism; Morbidity - disease rate; Nitric Oxide; Patients; Purpose; Research; Research Personnel; Resources; Risk Factors; Source; United States National Institutes of Health; arterial stiffness; cardiovascular risk factor; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypertension, a common risk factor for atherosclerosis, occurs without a known or reversible cause in over 90% of cases, and adjunct strategies are needed to reduce its complications, such as vascular dysfunction. Clinical trials have shown that HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular mortality and morbidity. This benefit is seen in patients with and without high blood cholesterol levels. Non-lipid actions of statins including effects on the blood vessel wall, the microvasculature and systemic inflammation are likely to be responsible for this benefit. The purpose of this study is to more fully investigate the effects of statins on endothelial dysfunction (both conduit and microvascular), arterial stiffness, inflammation and impaired nitric oxide metabolism, which are potential pathophysiologic mechanisms leading to increased cardiovascular risk in hypertensive individuals.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构为 研究中心，而研究中心不一定是研究者所在的机构。 高血压是动脉粥样硬化的常见危险因素，在90%以上的病例中，高血压的发生没有已知或可逆的原因，需要辅助策略来减少其并发症，如血管功能障碍。 临床试验表明，HMG-CoA还原酶抑制剂（他汀类）治疗可降低心血管疾病的死亡率和发病率。 这种益处在有和没有高血胆固醇水平的患者中可见。 他汀类药物的非脂质作用，包括对血管壁、微血管系统和全身炎症的作用，可能是这种获益的原因。 本研究的目的是更全面地研究他汀类药物对内皮功能障碍（导管和微血管），动脉僵硬度，炎症和一氧化氮代谢受损的影响，这些都是导致高血压患者心血管风险增加的潜在病理生理机制。